Hepatitis C virus recurrence after liver transplantation

Biomarkers of disease and fibrosis progression

Daniel Maluf, Kellie J. Archer, Federico Villamil, Richard Todd Stravitz, Valeria Mas

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

End-stage liver disease due to hepatitis C virus infection (HCV) is the principal indication for liver transplantation. In the USA, over a third of available liver allografts are transplanted into recipients with chronic HCV infection. Reinfection of the graft is universal, but the impact of reinfection on short-and long-term liver function is highly variable. HCV infection in liver transplantation recipients is characterized by an accelerated fibrogenesis, with approximately a third of patients developing cirrhosis within 5 years of follow-up. HCV is associated with decreased patient and graft survival when compared with other indications of orthotopic liver transplantation. The mechanisms responsible for the accelerated liver damage in HCV-infected orthotopic liver transplantation recipients remain largely unknown.

Original languageEnglish (US)
Pages (from-to)445-458
Number of pages14
JournalExpert Review of Gastroenterology and Hepatology
Volume4
Issue number4
DOIs
StatePublished - Aug 1 2010

Fingerprint

Virus Diseases
Hepacivirus
Liver Transplantation
Disease Progression
Fibrosis
Biomarkers
Recurrence
Liver
End Stage Liver Disease
Graft Survival
Chronic Hepatitis C
Infection
Allografts
Transplants

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Hepatitis C virus recurrence after liver transplantation : Biomarkers of disease and fibrosis progression. / Maluf, Daniel; Archer, Kellie J.; Villamil, Federico; Stravitz, Richard Todd; Mas, Valeria.

In: Expert Review of Gastroenterology and Hepatology, Vol. 4, No. 4, 01.08.2010, p. 445-458.

Research output: Contribution to journalReview article

@article{4b7cff77757e4282843fe50c7e1e721f,
title = "Hepatitis C virus recurrence after liver transplantation: Biomarkers of disease and fibrosis progression",
abstract = "End-stage liver disease due to hepatitis C virus infection (HCV) is the principal indication for liver transplantation. In the USA, over a third of available liver allografts are transplanted into recipients with chronic HCV infection. Reinfection of the graft is universal, but the impact of reinfection on short-and long-term liver function is highly variable. HCV infection in liver transplantation recipients is characterized by an accelerated fibrogenesis, with approximately a third of patients developing cirrhosis within 5 years of follow-up. HCV is associated with decreased patient and graft survival when compared with other indications of orthotopic liver transplantation. The mechanisms responsible for the accelerated liver damage in HCV-infected orthotopic liver transplantation recipients remain largely unknown.",
author = "Daniel Maluf and Archer, {Kellie J.} and Federico Villamil and Stravitz, {Richard Todd} and Valeria Mas",
year = "2010",
month = "8",
day = "1",
doi = "10.1586/egh.10.39",
language = "English (US)",
volume = "4",
pages = "445--458",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Hepatitis C virus recurrence after liver transplantation

T2 - Biomarkers of disease and fibrosis progression

AU - Maluf, Daniel

AU - Archer, Kellie J.

AU - Villamil, Federico

AU - Stravitz, Richard Todd

AU - Mas, Valeria

PY - 2010/8/1

Y1 - 2010/8/1

N2 - End-stage liver disease due to hepatitis C virus infection (HCV) is the principal indication for liver transplantation. In the USA, over a third of available liver allografts are transplanted into recipients with chronic HCV infection. Reinfection of the graft is universal, but the impact of reinfection on short-and long-term liver function is highly variable. HCV infection in liver transplantation recipients is characterized by an accelerated fibrogenesis, with approximately a third of patients developing cirrhosis within 5 years of follow-up. HCV is associated with decreased patient and graft survival when compared with other indications of orthotopic liver transplantation. The mechanisms responsible for the accelerated liver damage in HCV-infected orthotopic liver transplantation recipients remain largely unknown.

AB - End-stage liver disease due to hepatitis C virus infection (HCV) is the principal indication for liver transplantation. In the USA, over a third of available liver allografts are transplanted into recipients with chronic HCV infection. Reinfection of the graft is universal, but the impact of reinfection on short-and long-term liver function is highly variable. HCV infection in liver transplantation recipients is characterized by an accelerated fibrogenesis, with approximately a third of patients developing cirrhosis within 5 years of follow-up. HCV is associated with decreased patient and graft survival when compared with other indications of orthotopic liver transplantation. The mechanisms responsible for the accelerated liver damage in HCV-infected orthotopic liver transplantation recipients remain largely unknown.

UR - http://www.scopus.com/inward/record.url?scp=77955235004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955235004&partnerID=8YFLogxK

U2 - 10.1586/egh.10.39

DO - 10.1586/egh.10.39

M3 - Review article

VL - 4

SP - 445

EP - 458

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 4

ER -